Skip to main content
TipRanks
Go Ultimate75% OFF

Compare Mineralys Therapeutics, Inc. (MLYS) vs. Competitors

614 Followers

Comparison Results

Comparison results
NamePriceMarket CapP/E RatioYearly GainAnalyst ConsensusAnalyst Price TargetCompareTop Analysts' Price TargetSmart ScoreFollow
MLYSMineralys Therapeutics, Inc.$14.16$1.25B-3.25-66.38%Strong BuyUnlock the MLYS analyst price target with TipRanks PremiumMLYSUnlock the MLYS top-analyst price target with TipRanks Premium
INVAInnoviva$18.41$1.31B7.25-13.45%Strong BuyUnlock the INVA analyst price target with TipRanks PremiumMLYS vs INVAUnlock the INVA top-analyst price target with TipRanks Premium
RAREUltragenyx Pharmaceutical$17.22$1.76B-3.32-45.95%Moderate BuyUnlock the RARE analyst price target with TipRanks PremiumMLYS vs RAREUnlock the RARE top-analyst price target with TipRanks Premium
ARDXArdelyx$3.06$769.20M-13.62-45.06%Strong BuyUnlock the ARDX analyst price target with TipRanks PremiumMLYS vs ARDXUnlock the ARDX top-analyst price target with TipRanks Premium
GPCRStructure Therapeutics, Inc. Sponsored ADR$17.12$1.22B-4.39-53.11%Strong BuyUnlock the GPCR analyst price target with TipRanks PremiumMLYS vs GPCRUnlock the GPCR top-analyst price target with TipRanks Premium
KLRAKailera Therapeutics, Inc.$11.58$1.50B-3.82-55.46%Strong BuyUnlock the KLRA analyst price target with TipRanks PremiumMLYS vs KLRAUnlock the KLRA top-analyst price target with TipRanks Premium

Performance Comparison

-100%-50%0%50%100%150%200%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Performance comparison by fund
TickerCompany NamePriceChange% Change
MLYSMineralys Therapeutics, Inc.14.16-27.71-66.18%
INVAInnoviva18.41-2.55-12.17%
RAREUltragenyx Pharmaceutical17.22-16.37-48.73%
ARDXArdelyx3.06-2.36-43.54%
GPCRStructure Therapeutics, Inc. Sponsored ADR17.12-17.20-50.12%
KLRAKailera Therapeutics, Inc.11.58-14.42-55.46%
Compare key indicators and discover each stock’s average analyst price target, as well as the latest recommendations by top Wall Street experts